Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)
Clinical trial NCT07560410 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07560410
- Sponsor
- China Medical University Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-15
- Primary completion
- 2029-01-15
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.